
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ORNBV | Helsinki | EUR | Real-time | |
ORNAV | Helsinki | EUR | Real-time | |
ORNBVh | BATS Europe | EUR | Delayed | |
ORINY | OTC Markets | USD | Delayed | |
0M2O | London | EUR | Real-time | |
1ORNBV | Milan | EUR | Real-time |
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid arthritis and cancer; and Dexdor, Precedex, and Dexmedetomidine products for human use. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other companies. It has discovery service and commercial license agreement with Invenra to develop bispecific antibody cancer therapeutics; and collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
Name | Age | Since | Title |
---|---|---|---|
Ari Tapio Lehtoranta | 62 | 2017 | Independent Director |
Henrik Stenqvist | 58 | 2024 | Director |
Mikael Silvennoinen | 69 | 2014 | Independent Director |
Eija Ronkainen | 59 | 2016 | Independent Director |
Kari Jussi Aho | 65 | 2020 | Independent Director |
Karen Lykke Sorensen | 63 | 2022 | Independent Director |
Hilpi Rautelin | 64 | 2017 | Independent Vice Chairman of the Board |
Veli-Matti Johannes Mattila | 64 | 2021 | Independent Chairman |
Maziar Mike Doustdar | 55 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review